Sartorius Stedim Biotech


20/05/25 -"The cut in our target price is attributable to the downgrading of our estimates, which now factor in a slower recovery than previously anticipated."

Pages
60
Language
English
Published on
20/05/25
You may also be interested by these reports :
20/05/25
The cut in our target price is attributable to the downgrading of our estimates, which now factor in a slower recovery than previously anticipated.

16/05/25
The 2024 EPS benefitted from some one-off tailwinds, in addition to the good cost control. Hence, while the EPS was significantly above estimates, it ...

16/05/25
Bastide’s Q3 revenue extended the positive trend, thanks to the continued strong growth in specialised activities and the recovery in the Homecare ...

16/05/25
We have removed Palantir, a software company with real-time, AI-driven decisions capabilities, from the peer group list due to its elevated ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO